![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ALPHARMA RECEIVES FDA APPROVAL FOR GENERIC GLUCOVANCE
ALPHARMA RECEIVES FDA APPROVAL FOR GENERIC GLUCOVANCE
July 5, 2005
The FDA has granted final approval to Alpharma's abbreviated new drug application for glyburide/metformin HCl tablets in 1.25-mg/250-mg, 2.5-mg/500-mg and 5-mg/500-mg dosage forms. The product is a generic version of Bristol-Myers Squibb's Glucovance tablets, which is indicated as an adjunct to diet and exercise in the treatment of Type 2 diabetes. Glucovance tablets generated sales of approximately $270 million in 204, Alpharma said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct